produced basic summary statistics for hot flash scores and frequency from raw individual patient data pooled from all 10 studies, which included information on individual patient treatment ...

This article reviews the published literature on the use of venlafaxine, fluoxetine, and paroxetine for the treatment of hot flashes.

Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the use case for the menopause treatment expected to launch as early as this ...

Researchers have created an ultra-fast cancer treatment that can deliver much-needed treatment in just one second.

Announcing topline data from its OASIS 4 Phase 3 study, the German conglomerate said that its non-hormonal treatment option compared to placebo cut the occurrence of hot flashes (vasomotor symptoms) ...

Learn how this wearable technology helps women better understand and manage their menopause transition through real-time monitoring of hot flashes, sleep patterns and more.

Hot flashes are most commonly caused by hormone changes related to menopause, Thurston explains. Specifically, the rapid ...

Symptoms like insomnia, bloating and emotional shifts can occur before menopause begins, but they are often improperly ...

As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results in a slightly different patient population: women whose hot flashes were ...

Vasomotor symptoms are a common problem in women with HR-positive breast cancer receiving anti-cancer therapy.

Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in ...

The studies were conducted over short periods with no efficacy information beyond 13 weeks of treatment. The primary study endpoints were based on subjective data; however, use of hot flash ...